Posted by Michael Wonder on 28 Apr 2022
Baqsimi (nasal glucagon), rescue treatment for severe hypoglycaemia now covered in British Colombia, Alberta & Saskatchewan
27 April 2022 - Lilly Canada is pleased to announce that as of 5 April 2022, Baqsimi (glucagon nasal powder) is now covered under public programs in British Columbia, Alberta, and Saskatchewan.
Baqsimi is indicated for the treatment of severe hypoglycaemic reactions in people with insulin-treated diabetes mellitus 4 years old and above when impaired consciousness precludes oral carbohydrates.
